CA3186696A1 - Polymorphs of 5-aza-4'-thio-2-deoxycytidine - Google Patents

Polymorphs of 5-aza-4'-thio-2-deoxycytidine

Info

Publication number
CA3186696A1
CA3186696A1 CA3186696A CA3186696A CA3186696A1 CA 3186696 A1 CA3186696 A1 CA 3186696A1 CA 3186696 A CA3186696 A CA 3186696A CA 3186696 A CA3186696 A CA 3186696A CA 3186696 A1 CA3186696 A1 CA 3186696A1
Authority
CA
Canada
Prior art keywords
crystalline polymorph
cancer
aza
days
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3186696A
Other languages
English (en)
French (fr)
Inventor
Mark J. Suto
Doo Young Jung
Jin Soo Lee
Hyunyong Cho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pinotbio Inc
Southern Research Institute
Original Assignee
Pinotbio Inc
Southern Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pinotbio Inc, Southern Research Institute filed Critical Pinotbio Inc
Publication of CA3186696A1 publication Critical patent/CA3186696A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3186696A 2020-07-23 2021-07-23 Polymorphs of 5-aza-4'-thio-2-deoxycytidine Pending CA3186696A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063055754P 2020-07-23 2020-07-23
US63/055,754 2020-07-23
PCT/US2021/043021 WO2022020747A1 (en) 2020-07-23 2021-07-23 Polymorophs of 5-aza-4'-thio-2-deoxycytidine

Publications (1)

Publication Number Publication Date
CA3186696A1 true CA3186696A1 (en) 2022-01-27

Family

ID=79687860

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3186696A Pending CA3186696A1 (en) 2020-07-23 2021-07-23 Polymorphs of 5-aza-4'-thio-2-deoxycytidine

Country Status (10)

Country Link
US (1) US11447472B2 (enExample)
EP (1) EP4185583A4 (enExample)
JP (1) JP7679452B2 (enExample)
KR (1) KR102866823B1 (enExample)
CN (1) CN115989229A (enExample)
AU (1) AU2021314329A1 (enExample)
BR (1) BR112023001236A2 (enExample)
CA (1) CA3186696A1 (enExample)
MX (1) MX2023000979A (enExample)
WO (1) WO2022020747A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230123277A1 (en) * 2021-10-15 2023-04-20 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease and thalassemia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020322A (en) 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
US5591722A (en) * 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
CN103951583B (zh) 2006-12-06 2016-01-06 科内图斯医药公司 一种抑制剂的结晶形式
DK3782612T3 (da) 2008-05-15 2024-01-15 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
WO2011109012A1 (en) 2010-03-02 2011-09-09 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
US20110218170A1 (en) 2010-03-02 2011-09-08 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
CN106687139A (zh) 2014-07-14 2017-05-17 吉利德科学公司 用于治疗癌症的组合
US20160312261A1 (en) 2015-04-24 2016-10-27 Plasmia Biotech, S.L. Enzymatic production of cytosinic nucleoside analogues
US20190240210A1 (en) 2016-10-17 2019-08-08 Daiichi Sankyo Company, Limited Treatment Method by Combined Use of MDM2 Inhibitor and DNA Methyltransferase Inhibitor
JP7425734B2 (ja) * 2018-02-01 2024-01-31 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ２’－デオキシヌクレオシドを製造するための立体選択的合成およびプロセス
US20210363170A1 (en) 2018-04-19 2021-11-25 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer

Also Published As

Publication number Publication date
WO2022020747A8 (en) 2023-02-16
BR112023001236A2 (pt) 2023-04-04
US11447472B2 (en) 2022-09-20
US20220024903A1 (en) 2022-01-27
EP4185583A4 (en) 2024-10-30
EP4185583A1 (en) 2023-05-31
AU2021314329A1 (en) 2023-02-23
AU2021314329A8 (en) 2023-03-09
WO2022020747A1 (en) 2022-01-27
JP2023535724A (ja) 2023-08-21
MX2023000979A (es) 2023-04-20
KR102866823B1 (ko) 2025-09-30
JP7679452B2 (ja) 2025-05-19
KR20230061354A (ko) 2023-05-08
CN115989229A (zh) 2023-04-18

Similar Documents

Publication Publication Date Title
US11597742B2 (en) Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) phosphoryl)amino)propanoate
US10059733B2 (en) Gemcitabine analogs
CN105829310B (zh) 双环杂环化合物及其治疗用途
EP2916840B1 (en) Substituted gemcitabine aryl amide analogs
KR20180101643A (ko) 매크로라이드의 결정 형태들 및 그 용도들
AU2019256465A1 (en) 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
US11447472B2 (en) Polymorophs of 5-aza-4′-thio-2′-deoxycytidine
KR20180113988A (ko) 비정질 오나프리스톤 조성물 및 그 제조방법
US11242340B2 (en) Crystal forms of demethyleneberberine hydrochloride and preparation method therefor
CN101896477B (zh) 硝克柳胺化合物晶v型、其制法和其药物组合物与用途
CA3138114A1 (en) Thiarabine- and thiarabine prodrug-based treatments
CN106065016A (zh) 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法
CN105461713A (zh) 苯并萘啶类的新化合物及其组合物和用途
CN105085421B (zh) 奥比特嗪‑富马酸盐、水合物、晶型及其制备方法
CN102786458B (zh) 吡咯甲酰胺衍生物、其制备方法和用途
EP3414225B1 (en) Crystalline modifications of n-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine hydrochloride and n-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine salts
CN1498890A (zh) 一种阿德福韦酯的新结晶形态及制备方法
KR20230113186A (ko) 5-아자-4'-티오-2'-데옥시사이티딘을 함유하는 경구용 제형 및 이의 제조방법
EP3342778B1 (en) Crystal form of fludarabine phosphat, preparation method therefor, and application thereof
CN102417514B (zh) 吡啶衍生物、其制备方法和用途
CN102329327B (zh) 呋喃衍生物、其制备方法和用途
HK40016048A (en) Novel crystalline forms
HK40016048B (en) Novel crystalline forms
HK1214141B (en) Substituted gemcitabine aryl amide analogs

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240717

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240717

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250716

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250716

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250721

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250721

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250721

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250724

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250925

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250925

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250925

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251031

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251031

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260629

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260720

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260720